2018 Primary Sclerosing Cholangitis Drug Development- Pipeline Analysis Report
Primary sclerosing cholangitis (PSC) is a chronic progressive GI disorder that affects the bile volume in the gall bladder. The slowly progressing condition causes inflammation and scaring of bile ducts, which results in improper flow of the digestive liquid.
Around 30 companies and universities are focusing on developing treatment options for Primary sclerosing cholangitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Primary sclerosing cholangitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Primary sclerosing cholangitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Primary sclerosing cholangitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Around 30 companies and universities are focusing on developing treatment options for Primary sclerosing cholangitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Primary sclerosing cholangitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Primary sclerosing cholangitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Primary sclerosing cholangitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 PRIMARY SCLEROSING CHOLANGITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Primary Sclerosing Cholangitis Pipeline Snapshot
2.3 Primary Sclerosing Cholangitis Pipeline by Phase
2.4 Primary Sclerosing Cholangitis Pipeline by Company
2.5 Primary Sclerosing Cholangitis Pipeline by Mechanism of Action
3 PRIMARY SCLEROSING CHOLANGITIS- COMPANY WISE PIPELINE ANALYSIS
Acorda Therapeutics Inc
Albireo Pharma Inc
ChemomAb Ltd
Conatus Pharmaceuticals Inc
Dr. Falk Pharma GmbH
DURECT Corp
Gilead Sciences
HighTide Biopharmaceutical
Immune Pharmaceuticals Inc
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Noxopharm Ltd
Orbsen Therapeutics Ltd
PharmAkea Therapeutics
Sancilio & Company Inc
Shire Plc
Tobira Therapeutics
4 PRIMARY SCLEROSING CHOLANGITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PRIMARY SCLEROSING CHOLANGITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 PRIMARY SCLEROSING CHOLANGITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Primary Sclerosing Cholangitis Pipeline Snapshot
2.3 Primary Sclerosing Cholangitis Pipeline by Phase
2.4 Primary Sclerosing Cholangitis Pipeline by Company
2.5 Primary Sclerosing Cholangitis Pipeline by Mechanism of Action
3 PRIMARY SCLEROSING CHOLANGITIS- COMPANY WISE PIPELINE ANALYSIS
Acorda Therapeutics Inc
Albireo Pharma Inc
ChemomAb Ltd
Conatus Pharmaceuticals Inc
Dr. Falk Pharma GmbH
DURECT Corp
Gilead Sciences
HighTide Biopharmaceutical
Immune Pharmaceuticals Inc
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Noxopharm Ltd
Orbsen Therapeutics Ltd
PharmAkea Therapeutics
Sancilio & Company Inc
Shire Plc
Tobira Therapeutics
4 PRIMARY SCLEROSING CHOLANGITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PRIMARY SCLEROSING CHOLANGITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Primary Sclerosing Cholangitis Pipeline by Phase, H1- 2018
Figure 2: Primary Sclerosing Cholangitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Primary Sclerosing Cholangitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Primary Sclerosing Cholangitis Pipeline by Phase, H1- 2018
Figure 2: Primary Sclerosing Cholangitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Primary Sclerosing Cholangitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Primary Sclerosing Cholangitis Pipeline by Phase, H1- 2018
Table 2: Primary Sclerosing Cholangitis Pipeline by Companies, H1- 2018
Table 3: Primary Sclerosing Cholangitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Acorda Therapeutics Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 5: Albireo Pharma Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 6: ChemomAb Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
Table 7: Conatus Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 8: Dr. Falk Pharma GmbH Primary Sclerosing Cholangitis Pipeline, May 2018
Table 9: DURECT Corp Primary Sclerosing Cholangitis Pipeline, May 2018
Table 10: Gilead Sciences Primary Sclerosing Cholangitis Pipeline, May 2018
Table 11: HighTide Biopharmaceutical Primary Sclerosing Cholangitis Pipeline, May 2018
Table 12: Immune Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 13: Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 14: NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 15: Noxopharm Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
Table 16: Orbsen Therapeutics Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
Table 17: PharmAkea Therapeutics Primary Sclerosing Cholangitis Pipeline, May 2018
Table 18: Sancilio & Company Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 19: Shire Plc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 20: Tobira Therapeutics Primary Sclerosing Cholangitis Pipeline, May 2018
Table 1: Primary Sclerosing Cholangitis Pipeline by Phase, H1- 2018
Table 2: Primary Sclerosing Cholangitis Pipeline by Companies, H1- 2018
Table 3: Primary Sclerosing Cholangitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Acorda Therapeutics Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 5: Albireo Pharma Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 6: ChemomAb Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
Table 7: Conatus Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 8: Dr. Falk Pharma GmbH Primary Sclerosing Cholangitis Pipeline, May 2018
Table 9: DURECT Corp Primary Sclerosing Cholangitis Pipeline, May 2018
Table 10: Gilead Sciences Primary Sclerosing Cholangitis Pipeline, May 2018
Table 11: HighTide Biopharmaceutical Primary Sclerosing Cholangitis Pipeline, May 2018
Table 12: Immune Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 13: Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 14: NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 15: Noxopharm Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
Table 16: Orbsen Therapeutics Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
Table 17: PharmAkea Therapeutics Primary Sclerosing Cholangitis Pipeline, May 2018
Table 18: Sancilio & Company Inc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 19: Shire Plc Primary Sclerosing Cholangitis Pipeline, May 2018
Table 20: Tobira Therapeutics Primary Sclerosing Cholangitis Pipeline, May 2018
